BioSpace News Archive

GAITHERSBURG, Md., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and year ended December 31, 2019. FINANCIAL HIGHLIGHTS (in millions) Q4 2019 (unaudited) Q4 2018 (unaudited) $ Change % Change Total Revenues $360.4 $270.7 $89.7 33.1% Pre-tax Income 71.5 3.6 67.9 * Net Income 46.9 (3.4) 50.3 * Adjusted Net Income (1) 82.7 39.5 43.2 109.4% EBITDA (1) 107.9 36.1 71.8 198.9% Adjust

NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced the publication of results from its CAPLYTA (lumateperone) clinical trial (ITI-007-301) in adult patients with schizophrenia. The article, “Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial” (Correll et al. 2020), w

SAN DIEGO, Feb. 20, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration through our license to Santen Pharmaceutical Co. Ltd., and utilizing our product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its fo

The nation’s largest general veterinary practice and its charitable arm positively impacted the lives of millions of pets and people last year through volunteer efforts, free veterinary care and more

Founder Jeff Rice Steps Into Executive Chairman Role as Company Prepares for Rapid Growth in Healthcare Quality and Cost Transparency

Alladapt Immunotherapeutics Inc., a private biopharmaceutical company focused on the development of prescription therapeutics to address food allergy, today announced the completion of a $60 million Series C financing.

Industry-leading KOLs to present data from studies of multiple VIVEX technologies Presentations to showcase VIVEX products’ capacities to promote healing and bone fusion in certain spinal disorders ATLANTA and MIAMI, Feb. 20, 2020 (GLOBE NEWSWIRE) -- VIVEX Biologics, Inc., a leading regenerative medicine company specializing in the development of naturally sourced treatment options, today announced the presentation of multiple abstracts supporting the use of the company’s VIA Graft and

First-of-its-kind technology to provide broader access to magnetic resonance imaging (MRI) TORONTO, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Synaptive Medical, a leader in robotic surgical visualization, announced today the company has secured approval from Health Canada for Evry™, the company’s superconducting, head MRI. Evry has been designed to provide imaging directly at the point of care in areas outside of diagnostic imaging departments, which was previously unachievable due to the size of c

Cardiovalve announced today that it has received U.S. Food and Drug Administration (FDA) approval for an Early Feasibility Study (EFS) of its Transcatheter Tricuspid Valve Replacement System for a tricuspid regurgitation (TR) indication.

DentalEZ® is launching a new IoT product platform called Aeras™ that supports the company’s mission to address real, everyday challenges in dentistry.